TickerGuard
Buy Day today: Neutral (48) Mixed market breadth · no major macro event
APLS

Apellis Pharmaceuticals Inc

Healthcare · Biotechnology

3.40$ -0.1% vs. previous close Closing price · As of: Aug 13, 2026

Ownership

Ownership Structure

Who owns Apellis Pharmaceuticals Inc (APLS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 65.0% of the shares are freely tradable; institutional investors hold 110.4%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 110.4%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 11.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 65.0%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 12.6%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 128Mio.

Largest Shareholders

Institutions

Institutions APLS
Name Stake (%) Shares Change (%) Date
BlackRock Inc 10.57 13,536,964 +116.2 03/31/2026
venBio Select Advisor LLC 9.55 12,222,222 +0.0 03/31/2026
Morgan Stanley - Brokerage Accounts 7.84 10,042,399 +9.5 03/31/2026
State Street Corp 5.35 6,844,990 +48.4 03/31/2026
UBS Group AG 4.85 6,206,681 +48.3 03/31/2026
Vanguard Portfolio Management, LLC 4.22 5,404,559 +0.0 03/31/2026
Pentwater Capital Management LP 4.10 5,250,000 +0.0 03/31/2026
Vanguard Capital Management, LLC 3.73 4,768,944 +0.0 03/31/2026
Point72 Asset Management, L.P. 3.27 4,183,918 +600.0 03/31/2026
RTW INVESTMENTS, LLC 2.88 3,685,045 -51.9 03/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?